Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events

Last updated: May 4, 2021
Sponsor: Thrombosis Research Institute
Overall Status: Completed

Phase

N/A

Condition

Pulmonary Embolism

Deep Vein Thrombosis

Venous Thrombosis

Treatment

N/A

Clinical Study ID

NCT02155491
TRI08889
  • Ages 18-99
  • All Genders

Study Summary

The protocol is a large registry to describe acute, sub-acute and extended duration of anticoagulation management, clinical and economic duration of anticoagulation management, clinical and economic outcomes in patients with treated acute VTE (DVT and PE) in the real-world setting.

Main objectives are to clarify the:

  • treatment related details for acute VTE (either conventional anticoagulation therapy, treatment with a direct oral anti-coagulant or other modalities of treatment)

  • Rate of early and late symptomatic VTE recurrence

  • Rate and nature of complications of VTE including post thrombotic syndrome and chronic thromboembolic pulmonary hypertension

  • Rate of bleeding complications

  • Rate of all-cause mortality at six months

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Written informed consent
  • Age 18 years and over
  • Treated first time or recurrent DVT (lower or upper extremity), PE alone oroverlapping DVT and PE confirmed by appropriate diagnostic methods (patients must beassessed for eligibility within 30 days of diagnosis)
  • Patients included with recurrent VTE must have completed treatment for the previousVTE episode

Exclusion

Exclusion Criteria:

  • Patients for whom long-term follow-up is not envisaged within the enrolling hospitalor the associated primary care physician
  • Patients participating in an interventional study that dictates treatments, visitfrequency, or diagnostic procedures
  • Patients with only superficial vein thrombosis (SVT)

Study Design

Total Participants: 10679
Study Start date:
July 07, 2014
Estimated Completion Date:
September 30, 2020

Study Description

Other objectives are to clarify the additional outcomes of:

  • Stroke (Measured by number of incidences)

  • Transient Ischemic Attack (TIA) (Measured by number on incidences)

  • ST Elevated Myocardial Infarction (STEMI) (Measured by number of incidences)

  • Non-ST Elevated Myocardial Infraction (NSTEMI) (Measured by number of incidences)

  • Unstable Angina (Measured by number of incidences)

  • Quality of life and patient reported outcomes and costs associated with the management of VTE.

Connect with a study center

  • Dr Terence Hart

    Muscle Shoals, Alabama 35662
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.